Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Ann Surg ：NLR为HCC患者肝脏切除术后生存的独立预测因素

2013-07-04 ecoliDH5 dxy

AnnSurgNLRHCC肝脏切除术
关注

尽管相关报告认为，高中性粒细胞/淋巴细胞值(NLR)为各种肿瘤患者较差生存的预测因素，但尚未对肝细胞癌(HCC)患者进行过深入考察。对此，日本九州大学Ken Shirabe博士等人进行了一项研究，该研究针对因HCC而接受肝脏切除治疗的患者，旨在阐释术前NLR的预后价值。这项研究结果发表于2013年6月14日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。该项回顾性研究共招募了

尽管相关报告认为，高中性粒细胞/淋巴细胞值(NLR)为各种肿瘤患者较差生存的预测因素，但尚未对肝细胞癌(HCC)患者进行过深入考察。对此，日本九州大学Ken Shirabe博士等人进行了一项研究，该研究针对因HCC而接受肝脏切除治疗的患者，旨在阐释术前NLR的预后价值。这项研究结果发表于2013年6月14日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。

该项回顾性研究共招募了958例患者，这些HCC患者于1996年至2009年期间接受了肝脏切除治疗，患者均未接受过术前治疗。研究人员对包括NLR在内的临床病理参数进行了评价，以鉴定出肝脏切除术后总生存率及无复发生存率相关的预测因素。通过Cox比例风险模型进行了单变量和多变量分析。通过时间依赖型受试者工作特征曲线，确定得到最佳阈值。为确定NLR升高机制，还利用CD163染色法对150例患者进行了免疫组织检查。

单变量及多变量分析表明，NLR为总生存率及无复发生存率相关的独立预后因素。NLR最佳阈值为2.81，而在958例患者中，有238例(24.8%)患者的NLR高于2.81。对于NLR小于2.81的患者，在肝脏切除术后，其5年生存率为72.9%，而NLR值大于及等于2.81的患者则为51.5%(P < 0.0001)。与NLR小于2.81的患者相比，对于NLR值大于及等于2.81的患者，其肿瘤内阳性CD163细胞计数显著较高(P = 0.0004)。

这研究结果表明，NLR为HCC患者肝脏切除术后生存的独立预测因素。此外还发现，肿瘤相关的巨噬细胞积累与较高的NLR值有关。


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1808389, encodeId=2db718083899e, content=<a href='/topic/show?id=1d008142633' target=_blank style='color:#2F92EE;'>#肝脏切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81426, encryptionId=1d008142633, topicName=肝脏切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 18 22:36:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876649, encodeId=fd1e18e664941, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Dec 07 21:36:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264188, encodeId=984f126418846, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407724, encodeId=d78e140e724e6, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=)]
    2013-09-18 redcrab

    #肝脏切除术#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1808389, encodeId=2db718083899e, content=<a href='/topic/show?id=1d008142633' target=_blank style='color:#2F92EE;'>#肝脏切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81426, encryptionId=1d008142633, topicName=肝脏切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 18 22:36:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876649, encodeId=fd1e18e664941, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Dec 07 21:36:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264188, encodeId=984f126418846, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407724, encodeId=d78e140e724e6, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=)]
    2013-12-07 doctorzheng

    #切除术#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1808389, encodeId=2db718083899e, content=<a href='/topic/show?id=1d008142633' target=_blank style='color:#2F92EE;'>#肝脏切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81426, encryptionId=1d008142633, topicName=肝脏切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 18 22:36:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876649, encodeId=fd1e18e664941, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Dec 07 21:36:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264188, encodeId=984f126418846, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407724, encodeId=d78e140e724e6, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=)]
    2013-07-06 智智灵药

    #HCC#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1808389, encodeId=2db718083899e, content=<a href='/topic/show?id=1d008142633' target=_blank style='color:#2F92EE;'>#肝脏切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81426, encryptionId=1d008142633, topicName=肝脏切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 18 22:36:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876649, encodeId=fd1e18e664941, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Dec 07 21:36:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264188, encodeId=984f126418846, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407724, encodeId=d78e140e724e6, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=)]
    2013-07-06 朱睿睿

    #预测因素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1808389, encodeId=2db718083899e, content=<a href='/topic/show?id=1d008142633' target=_blank style='color:#2F92EE;'>#肝脏切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81426, encryptionId=1d008142633, topicName=肝脏切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Wed Sep 18 22:36:00 CST 2013, time=2013-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876649, encodeId=fd1e18e664941, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Dec 07 21:36:00 CST 2013, time=2013-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259469, encodeId=a2be1259469e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264188, encodeId=984f126418846, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407724, encodeId=d78e140e724e6, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Sat Jul 06 08:36:00 CST 2013, time=2013-07-06, status=1, ipAttribution=)]
    2013-07-06 yuandd

    #NLR#

    0

相关资讯

ANN THORAC SURG：一例同时侵犯左右心房的原发性心脏嗜铬细胞瘤

嗜铬细胞瘤是来源于神经嵴的产生儿茶酚胺的肿瘤。原发性心脏嗜铬细胞瘤是极为罕见的，全世界目前见于文献报道的仅为100例左右，北京协和医院心外科去年1月份成功进行了一例心脏嗜铬细胞瘤切除手术，患者为中年女性，肿瘤同时侵犯左右心房，其MIBG闪烁扫描的结果正常，但奥曲肽显像结果异常。肿瘤在体外循环下被成功切除。该病例报告已经发表在著名心胸外科专业杂志Annals of Thoracic Surgery上

Ann Oncol：厄洛替尼可改善EGFR突变呈阳性的晚期NSCLC患者生活质量

患者QoL评分及症状改善情况 在2013年3月1日在线出版的《肿瘤学年鉴》(Annals of Oncology)杂志上，发表了我国同济大学医学院附属肺科医院周彩存教授等人的一项研究结果，该文对OPTIMAL (CTONG-0802)研究中的生活质量(QoL)及最新的PFS分析结果进行了报告。OPTIMAL为一项临床III期随机、非盲研究，该研究针对瘤体存在EGFR激活突变的局部晚期或转移性

Ann Thorac Surg：术中冰冻切片在肺癌切除术中作用有限

非小细胞肺癌（NSCLC）切除后支气管残端阳性不利于患者的术后生存。为了确保R0 切除，胸外科医生通常采用术中冰冻切片分析支气管残端。然而，对于术中冰冻切片在非小细胞肺癌切除患者中是否应该常规应用，这方面的研究较少。针对这种情况，来美国佐治亚州亚特兰大市埃默里大学医学院普胸外科的Fernandez博士等人进行了一项研究，研究结果发表于2013年6月的《胸外科年鉴》（Ann Thorac Surg）

Ann Intern Med：是否有必要对结肠镜结果阴性的患者在10年后再次行结肠镜检查？

研究人员已经发现，在诊疗初始结肠镜检查结果阴性患者的结直肠癌方面，存在可替代结肠镜检查的有效方案。Amy Knudsen（美国，波士顿，马萨诸塞州总医院）及其同事说，与其对这类患者每10年一次采用结肠镜进行不断地筛查，倒不如选择风险更小和更加经济有效的重复筛查方法。 既往研究结果已经显示，结肠镜结果阴性人群的结直肠癌风险明显低于未接受筛查人群的风险，由此产生了一个疑问—是否有必要按照当前指南的建

Ann Surg：HR状况与HER2靶向药物影响核磁共振成像准确性

即将于2013年1月出版的《外科学年鉴》(Annals of Surgery)杂志发表了韩国国立首尔大学医院Hyeong-Gon Moon博士等人的一项研究结果，该研究针对在进行新辅助治疗后，核磁共振成像(MRI)的准确性是否受原发性乳腺癌相关分子特征以及以人表皮生长因子受体2(HER2)为靶点的药物影响进行了考察。 对于新辅助治疗后，影响乳腺癌核磁共振成像准确性因素的更深入理解，有助于核磁共振

Ann Surg.：术前饮食因素影响结肠癌患者感染并发症发病率

在营养补充方式是否对GALT数目与/或表型产生影响方面，目前尚缺乏相关临床证据。而GALT衰退对临床预后的影响也同样不甚明确。针对这种情况，日本防卫医科大学Koichi Okamoto博士等人进行了一项研究，他们对发生术后传染性并发症的情况下，术前饮食因素对肠道相关淋巴组织(GALT)细胞数目的影响进行考察。该项研究结果发表于2012年11月26日在线出版的《外科学年鉴》(Annals of Su

Baidu
map
Baidu
map
Baidu
map